Home > Insider Trading > Filing (0000899243-20-011098)

Filing Details

Accession Number:: 0000899243-20-011098
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2020-04-21 20:01:44
Reporting Period:: 2020-04-17

Accepted Time:: 2020-04-21 20:01:44
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1399529	Dicerna Pharmaceuticals Inc	DRNA	Pharmaceutical Preparations (2834)	205993609

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1598479	D Bob Brown	C/O Dicerna Pharmaceuticals, Inc. 33 Hayden Avenue Lexington MA 02421	See Remarks	No	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2020-04-17	8,185	$3.42	13,185	No	4	M	Direct
Common Stock	Disposition	2020-04-17	8,185	$21.18	5,000	No	4	S	Direct
Common Stock	Acquisiton	2020-04-20	13,281	$2.97	18,281	No	4	M	Direct
Common Stock	Disposition	2020-04-20	13,281	$23.00	5,000	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	S	Direct
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Employee Stock Option (Right to Buy)	Disposition	2020-04-17	8,185	$0.00	8,185	$3.42
Common Stock	Employee Stock Option (Right to Buy)	Disposition	2020-04-20	13,281	$0.00	13,281	$2.97

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
65,480		2023-09-24	No	4	M	Direct
44,827		2027-01-03	No	4	M	Direct

Footnotes

The reporting person sold an aggregate of 8,185 shares of common stock on April 17, 2020 (the "Shares Sold on April 17, 2020") as reported in this Form 4. The Shares Sold on April 17, 2020 represent 0.79% of 1,042,114 shares of common stock, which is the number of shares of common stock owned by the reporting person prior to the Shares Sold on April 17, 2020 transaction reported in this Form 4, as well as shares issuable upon exercise or settlement of vested and unvested options and restricted stock units held by the reporting person as of the date of this report.
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 27, 2019.
The reporting person sold an aggregate of 13,281 shares of common stock on April 20, 2020 (the "Shares Sold on April 20, 2020") as reported in this Form 4. The Shares Sold on April 20, 2020 represent 1.28% of 1,033,929 shares of common stock, which is the number of shares of common stock owned by the reporting person prior to the Shares Sold on April 20, 2020 transaction reported in this Form 4, as well as shares issuable upon exercise or settlement of vested and unvested options and restricted stock units held by the reporting person as of the date of this report.
The vesting of this option was subject to achievement of pre-established performance goals. As of the transaction date, the option was fully vested.
The option vests in 48 monthly installments over the four-year period starting on the last day of January 2017, subject in each case to the reporting person's continued service with the issuer through the applicable vesting date.